Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclosporine + carfilzomib + dexamethasone
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of cyclosporine, carfilzomib, and dexamethasone being investigated for the treatment of relapsed and refractory multiple myeloma (RRMM). This regimen is specifically targeted at patients who have received at least two prior lines of therapy including carfilzomib, were non-responsive or refractory to carfilzomib, and have elevated expression of Peptidylprolyl Isomerase A (PPIA) in their myeloma cells. Cyclosporine is administered with dose titration to achieve a target trough concentration, while carfilzomib and dexamethasone follow standard administration protocols.
- Other names
- cyclosporine in combination with carfilzomib and dexamethasone
02
Targets
GR (Glucocorticoid receptor)PPIA (Peptidyl-prolyl cis-trans isomerase A)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on cyclosporine + carfilzomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclosporine + carfilzomib + dexamethasone.